Imaging in systemic amyloidosis

British Medical Bulletin

Volumn 107, Issue 1, 2013, Pages 41-56

  Sachchithanantham, Sajitha ^a   Wechalekar, Ashutosh D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

CMR; DPD; Imaging; PET; SAP; Systemic amyloidosis

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMYLOID; APROTININ TC 99M; BUTEDRONATE TECHNETIUM TC 99M; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; MEDRONATE TECHNETIUM TC 99M; PITTSBURGH COMPOUND B; PREALBUMIN; RADIOPHARMACEUTICAL AGENT; SERUM AMYLOID P; SERUM AMYLOID P I 123; THIOFLAVINE; UNCLASSIFIED DRUG; IODINE 123; PYROPHOSPHATE; TECHNETIUM 99M; TRACER;

AMYLOIDOSIS; ARTICLE; AUTONOMIC NEUROPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SCINTISCANNING; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SERUM AMYLOID P SCINTIGRAPHY; TREATMENT RESPONSE; ALZHEIMER DISEASE; IMAGING; MEDLINE;

EID: 84887857621     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldt021     Document Type: Article

References (39)

1. Sipe JD, Benson MD, Buxbaum JN et al. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012;19: 167-70.
2. Hawkins PN, Myers MJ, Lavender JP et al. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet 1988;i: 1413-8.
3. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990;323: 508-13.
4. Hazenberg BP, van Rijswijk MH, Piers DA et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 2006;119:355.e15-24.
5. Hawkins PN, Wootton R, Pepys MB. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest 1990;86: 1862-9.
6. Hawkins PN, Richardson S, MacSweeney JE et al. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. Q J Med 1993;86: 365-74.
7. Lovat LB, Persey MR, Madhoo S et al. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut 1998;42: 727-34.
8. Yao Y, Wang SX, Zhang YK et al. A clinicopathological analysis in a large cohort of Chinese patients with renal amyloid light-chain amyloidosis. Nephrol Dial Transplant 2013;28: 689-97.
9. Goodman HJ, Gillmore JD, Lachmann HJ et al. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006;134: 417-25.
10. Gillmore JD, Lovat LB, Persey MR et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358: 24-9.
11. Van Gameren II, Hazenberg BP, Jager PL et al. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid 2002;9: 165-74.
12. Tan SY, Irish A, Winearls CG et al. Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int 1996;50: 282-9.
13. Gillmore JD, Booth DR, RelaMet al. Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen a-chain variant in an English family. Q J Med 2000;93: 269-75.
14. Gillmore JD, Stangou AJ, Tennent GA et al. Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation 2001;71: 986-92.
15. Kristen AV, Perz JB, Schonland SO et al. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant 2007;26: 1313-9.
16. Rapezzi C, Merlini G, Quarta CC et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120: 1203-12.
17. Selvanayagam JB, Hawkins PN, Paul B et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50: 2101-10.
18. Bellavia D, Pellikka PA, Abraham TP et al. . Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol 2008;101: 1039-45.
19. Koyama J, Davidoff R, Falk RH. Longitudinal myocardial velocity gradient derived from pulsed Doppler tissue imaging in AL amyloidosis: a sensitive indicator of systolic and diastolic dysfunction. J Am Soc Echocardiogr 2004;17: 36-44.
20. Buss SJ, Emami M, Mereles D et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol 2012;60: 1067-76.
21. Chen W, Dilsizian V. Molecular imaging of amyloidosis: will the heart be the next target after the brain? Curr Cardiol Rep 2012;14: 226-33.
22. Perugini E, Guidalotti PL, Salvi F et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46: 1076-84.
23. Kristen AV, Haufe S, Schonland SO et al. Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol 2013;164: 179-84.
24. Rapezzi C, Quarta CC, Guidalotti PL et al. Role of (99 m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4: 659-70.
25. Tanskanen M, Peuralinna T, Polvikoski T et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a populationbased autopsy study. Ann Med 2008;40: 232-9.
26. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008;14: 3219-30.
27. Sojan SM, Smyth DR, Tsopelas C et al. Pharmacokinetics and normal scintigraphic appearance of 99mTc aprotinin. Nucl Med Commun 2005;26: 535-9.
28. Schaadt BK, Hendel HW, Gimsing P et al. 99mTc-aprotinin scintigraphy in amyloidosis. J Nucl Med 2003;44: 177-83.
29. Chen W, Cao Q, Dilsizian V. Variation of heart-to-mediastinal ratio in (123)I-mIBG cardiac sympathetic imaging: its affecting factors and potential corrections. Curr Cardiol Rep 2011;13: 132-7.
30. Hongo M, Fujii T, Hirayama J et al. Radionuclide angiographic assessment of left ventricular diastolic filling in amyloid heart disease: a study of patients with familial amyloid polyneuropathy. J Am Coll Cardiol 1989;13: 48-53.
31. Eriksson P, Karp K, Bjerle P et al. Disturbances of cardiac rhythm and conduction in familial amyloidosis with polyneuropathy. Br Heart J 1984;51: 658-62.
32. Noordzij W, Glaudemans AW, van Rheenen RW et al. (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging 2012;39: 1609-17.
33. Austin BA, Tang WH, Rodriguez ER et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovascular imaging 2009;2: 1369-77.
34. Banypersad SM, Sado DM, Flett AS et al. Quantification of myocardial extracellular volume fraction in systemic Al amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2013;6: 34-9.
35. Klunk WE, Engler H, Nordberg A et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55: 306-19.
36. Furukawa K, Ikeda S, Okamura N et al. Cardiac positron-emission tomography images with an amyloid-specific tracer in familial transthyretin-related systemic amyloidosis. Circulation 2012;125: 556-7.
37. Antoni G, Lubberink M, Estrada S et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 2013;54: 213-20.
38. Mekinian A, Jaccard A, SoussanMet al. 18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case-series and literature review. Amyloid 2012;19: 94-8.
39. Wall JS, Kennel SJ, Stuckey AC et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood 2010;116: 2241-4.